International Human Capacity Development (IHCD)

Tehran University of Medical Sciences
Office of Vice-Chancellor for Global Strategies & International Affairs
International Human Capacity Development (IHCD)

Code : 9345-345842 Publish Date : Tuesday, March 17, 2015 Visit : 1748

Intl. Congress form | International Congress Report | International Congress Report For Faculty | 2014 World Cancer Congress

2014 World Cancer Congress

The report of 2014 World Cancer Congress by Dr. Peiman Haddad

Application Code :

306-0115-0025

Created Date : Monday, October 21, 2013 12:06:11Update Date : Monday, March 16, 2015 10:31:41
IP Address : 194.225.53.14Submit Date : Monday, March 16, 2015 10:32:09Email : haddad@sina.tums.ac.ir

Personal Information

Name :	Peiman
Surname :	Haddad
School/Research center :	School of Medicine
If you choose other, please name your Research center :
Possition :	Professor
Tel :	+98-21-61192585

Information of Congress

Title of the Congress :	2014 World Cancer Congress
Title of your Abstract :	Addition of oxaliplatin to neoadjuvant radiochemotherapy in MRI defined T3, T4 or N+ rectal cancer: A randomized clinical trial
country :	Australia
From :	Wednesday, December 3, 2014
To :	Saturday, December 6, 2014
Abstract(Please copy/paste the abstract send to the congress) :	Background: Clinical trials investigating the effects of addition of oxaliplatin to neoadjuvant radiochemotherapy in locally advanced rectal cancers (LARC) have brought controversial results for pathologic complete response as an endpoint. Aim: This phase III randomized study investigated downstaging as a short term surrogate for progression free survival (PFS). Methods: Patients with MRI defined T3, T4 or N+ histologically proven adenocarcinoma of rectum within 15 cm from anal verge were randomly assigned to receive 50-50.4 Gy external beam radiation in 25-28 fractions and concurrent capecitabine 825 mg/m2 twice daily 5 days a week with or without oxaliplatin 60 mg/m2 weekly as neoadjuvant radiochemotherapy (capox and cap group respectively). T and N downstage were defined as at least one stage regression in pathologic report after surgery comparing to MRI image before the pre-operative treatment. Adverse effects of treatment were recorded on a weekly basis according to National Cancer Institute Common Toxicity Criteria, version 4. Results: 63 patients were randomly assigned to cap (n=31) and capox (n=32) groups. There was no grade 4 toxicity. The only grade 3 toxicity which occurred more in capox group was diarrhea (21.87% vs 0%; p=0.006) . Histopathologic stage of 52 patients (27 patients in cap and 25 patients in capox groups) were compared to their preoperative stage defined by MRI. There was a greater rate of T downstage in capox group (59.37% vs 41.93%; p=0.037). The N downstage occurred non-significantly more in capox group (62.5% vs 51.6%; p=0.424). 11 patients in capox group (34.37%) achieved pathologic complete response, comparing to 4 in cap group (12.9%); p=0.072. Conclusions: The addition of oxalipatin to neoadjuvant radiochemotherapy in LARC led to higher rate of tumor downstaging. Longer follow up is needed to evaluate PFS.
Keywords of your Abstract :	Recal cancer, radiochemotherapy, capecitabine, oxaliplatin
Acceptance Letter :	http://gsia.tums.ac.ir/images/UserFiles/11850/Forms/306/Acceptance WCC 2014 abstract_1.pdf
The presentation :	eposter
The Cover of Abstract book :
Published abstract in the abstract book with the related code :
Where has your abstract been indexed? :	ISI
If you choose other, please name :

The Congress Reporting Form

How many volunteers were present at the Congress? :	This was the International Union Against Cancer (UICC) bi-annual congress held at the highest level in the World. There were many volunteers from all over the World specially Australia. http://www.worldcancercongress.org/congress-home
Delegates from which countries presented in the congress? :	50 international organisations representing 5 continents and 17 countries (Australia, USA, Canada, UK, France, ...) were present, with individual delegates from many more countries too.
Were the delegates of any other organizations present in the congress? :	Yes
If yes, please write the names of the organizations in the box :	50 international organisations representing 5 continents and 17 countries, including WHO, USA Cancer Society, Canada partnership against cancer, NCD Alliance, etc. and many other cancer societies from USA, Canada, Europe, Africa and Australia.
What were the responses to your talking points? Were specific questions or concerns raised? :	Responses were attentive and congratulatory on performing a randomized clinical trial. I was asked about the specific chemotherapy regimen I used concurrent with radiation for neoadjuvat treatment of rectal carcinoma.
If you met staff members, please list their full names & positions. :	I personally met Professor Mary Gospodarowicz, the president of International Union Against Cancer (UICC) and chairwoman of the congress, whom I well knew from my fellowship time, and many other members, including the future president of UICC repacing professor Gospodarowicz, head of ESTRO, and organizers of the NCD (Non-communicable Diseases) Alliance.
Please inform us if there are any follow up actions we need to talk with the members of the congress :	One very important session of the congress for me was by UICC Global Task Force for improvement of the quality of radiotherapy. I am in contact with this group and will use their help for our radiation oncology here. Another important meeting was for delegates from Eastern Mediterranean countries, with good networking opportunities. I will also follow up with organizers of the NCD allianace, with the aim of establishing a branch in Iran.
Your experiences about the travel processes(Providing ticket, accommodation,...) :	Flight to Australia from Dubai was too long and exhausting, and also very expensive. Hotels in Melbourne were expensive too.
Please give a briefing of your own observations and outcomes of the congress: :	A very good congress with important educational and networking results for me in cancer research and treatment. One very important session of the congress for me was by UICC Global Task Force for improvement of the quality of radiotherapy. I am in contact with this group and will use their help for our radiation oncology here. Another important meeting was for delegates from Eastern Mediterranean countries, with good networking opportunities. I will also follow up with organizers of the NCD allianace, with the aim of establishing a branch in Iran.